Furthermore, a significantly reduced infarct region, increased cardiac function, and decreased myocardial fibrosis were observed post-I/R in mice treated with a S100A9 neutralizing antibody (nAb) (Li et al., 2019). Here, S100A9 is linked to Myocardial fibrosis.